IBC starts Phase I/II study

IBC Pharmaceuticals, a joint venture between Immunomedics (IMMU) and Beckman Coulter (BEC), began Phase I/II testing in France of IBC's Pentacea bispecific antibody against tumors expressing carcinoem...